

1 **Mediators between body mass index and atrial fibrillation: a Mendelian**

2 **Randomization study**

3 Ziting Gao, M.D.¹, Jun Xiao, M.D., Ph.D.^{2,3*}, Wuqing Huang, M.D., Ph.D.^{1*}

4 ¹ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
5 Medical University, Fuzhou, Fujian, China.

6 ² Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University,
7 Fuzhou, Fujian, China.

8 ³ Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian,
9 China.

10 **Short title:** Mediators between BMI and atrial fibrillation.

11 ***Share the senior authorship.**

12 **Correspondence:** Wuqing Huang & Jun Xiao

13 Wuqing Huang

14 Fujian Medical University,

15 No 1, Xue Yuan Road, University Town, 350108

16 Fuzhou City, Fujian Province, China.

17 Email: wuqing.huang@fjmu.edu.cn Telephone: +8617338896101

18 Jun Xiao

19 Fujian Medical University Union Hospital,

20 No. 29 Xinquan Road, Fuzhou City, 350001,

21 Fujian Province, China.

22 Email: xiaojun@fjmu.edu.cn Telephone: +8618229908473

23 **Word count:** abstract (231), text (2891), figures (53), tables (0)

24 **Abbreviations:** AF, Atrial fibrillation; CRP C-reactive protein; BMI, body mass index;

25 MR, Mendelian randomization; GWASs, Genome-Wide Association Studies; LDL-C,

26 low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; TC

27 total cholesterol; TG triglycerides; GIANT, Genetic Investigation of ANthropometric

28 Traits; SNPs, single nucleotide polymorphisms; IVW-MR, inverse-variance weighted

29 mendelian randomization; PERM, percentage of excess risk mediated; OR, odds ratio.

30

31

32

33 Abstract

34 **Background:** Although obesity is a recognized risk factor of atrial fibrillation (AF),
35 the mechanisms are not fully understood. Thus, we aimed to identify the potential
36 mediators between body mass index (BMI) and AF.

37 **Methods:** We conducted a two-sample Mendelian randomization (MR) analysis using
38 publicly available summary-level data from genome-wide association studies.
39 Univariable MR analyses were applied to identify potential mediators, and then the
40 multivariable MR analyses were conducted to explore the mediated roles of
41 circulating cytokines, metabolic markers and comorbidities in the association between
42 BMI and AF.

43 **Results:** This MR study found a significant causal association between BMI and AF
44 (OR=1.41, 95%CI=1.33-1.50; $P<0.001$), which was attenuated to 1.21
45 (95%CI=1.03-1.43) after being adjusted for leptin, in which 48.78% excess risk was
46 mediated. After further adjustment for leptin and sleep apnoea or coronary heart
47 disease, the association was attenuated to null (adjusted for leptin and sleep apnoea:
48 OR=1.05, 95%CI=0.85-1.30; adjusted for leptin and coronary heart disease: OR=1.08,
49 95%CI=0.90-1.30), resulting in 87.80% and 80.49% excess risk being mediated,
50 respectively.

51 **Conclusion:** These results identified an important mediated role of leptin, particularly
52 for individuals with sleep apnoea or coronary heart disease, providing some clues for
53 the underlying mechanisms behind the impact of obesity on AF risk.

54 **Funding:** Natural Science Foundation of Fujian Province (grant no. 2022J01706) and

55 the Start-up Fund for high-level talents of Fujian Medical University

56 (XRCZX2021026).

57 **Keywords:** obesity, atrial fibrillation, leptin, mendelian randomization

58 Introduction

59 Atrial fibrillation (AF) is the most common type of arrhythmia and associated with
60 significant elevated risk of morbidity and mortality, resulting in major public health
61 burden and referred to as a cardiovascular epidemic of the 21st century. The incidence
62 is continuously increasing, the Framingham Heart Study has reported a threefold
63 increase in the incidence of AF during the past 50 years.¹ AF is closely related to a
64 range of classic cardiovascular risk factors, including modifiable lifestyle factors (eg,
65 obesity, hypertension, diabetes, coronary artery disease, hyperthyroidism, kidney
66 disease), and non-modifiable factors (eg, age, ethnic).² Although a number of risk
67 factors have been linked to a higher risk of AF, the etiology has not been clarified yet.

68 Obesity is a well-established risk factor for AF.³⁻⁸ ARIC (Atherosclerosis Risk In
69 Communities) study reported that nearly 20% of atrial fibrillation cases can be
70 attributed to overweight or obesity.⁹ However, the underlying pathways behind
71 obesity and AF remained unclear. Several mechanisms have been proposed to explain
72 this link.² For example, obesity always co-exists with multiple metabolic disorders,
73 such as dyslipidemia, hypertension and diabetes, all of which have ever been reported
74 to increase the risk of AF. Prior epidemiological studies found that obese adults were
75 predisposed to some comorbidities, such as coronary heart disease, obstructive sleep
76 apnoea, hyperthyroidism and so on, besides, complex links were reported between AF
77 and these comorbidities, indicating a potential mediated role of comorbidities between
78 obesity and AF. Furthermore, obesity is related to the circulating level of
79 adipocyte-derived cytokines (i.e., adipokines) as well as inflammatory cytokines.

80 Circulating leptin (the marker of leptin resistance) and C reactive protein (CRP) (an
81 important marker of inflammation) are always correlated, increased level of both is
82 common in obesity and independently associated with risk of multiple cardiovascular
83 diseases, including AF.^{10,11}

84 Given that obesity is becoming an epidemic with an estimation of one third of
85 the population globally being overweight or obese, targeting obesity and its pathways
86 is a promising strategy to largely reduce the incidence of AF.¹² While obesity is a
87 complex condition, evidence of “obesity paradox” is emerging for cardiovascular
88 diseases, for example, some studies found a more favorable prognosis in AF patients
89 with a higher body mass index (BMI).¹³ Thus, it is important to fully understand the
90 possible pathways in the association of BMI and AF. There are a paucity of studies
91 exploring the potential mediators between obesity and AF, which is challenging to be
92 studied in traditional observational epidemiological studies due to the inherent
93 problems of unmeasurable confounding factors and reverse causality. Mendelian
94 randomization (MR) approach complements traditional epidemiological methods as it
95 contributes to overcoming these flaws by using genetic variants as instrumental
96 variables.¹⁴ Therefore, in this study, we aimed to extensively explore the potential
97 mediators and identify the dominating mediators in the relationship between BMI and
98 AF via multivariable MR study.

99 **Methods**

100 **Study design**

101 We used publicly available summary-level data from Genome-Wide Association

102 Studies (GWAS) (**Supplementary Table 1**) to conduct two-sample MR study. MR
103 uses genetic variants strongly correlated with exposure factors as instrumental
104 variables (IVs) to estimate causal effects between exposure and outcomes.¹⁴ All
105 publicly available studies used in this research had been approved by the relevant
106 institutional review boards and participants had provided informed consents.

107 According to findings from previous studies regarding risk factors of AF, we
108 categorized the potential mediators into three classes in the present study, including
109 circulating cytokines, metabolic markers and comorbidities. Circulating cytokines
110 include leptin, adiponectin, resistin and CRP; Metabolic markers include low-density
111 lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total
112 cholesterol (TC), triglycerides (TG), fasting blood glucose, systolic blood pressure
113 and diastolic blood pressure; Obesity-related comorbidities include sleep apnoea,
114 coronary heart disease, stroke, chronic kidney disease and hyperthyroidism. The
115 univariable MR analyses were first applied to investigate the total effect of BMI on
116 AF, and to evaluate the causal relationship between BMI and potential mediators as
117 well as between potential mediators and AF to identify the significant mediators. Next,
118 the multivariable MR analyses were conducted to assess the mediated effects of these
119 significant mediators between BMI and AF.

120 **Data sources**

121 The GWAS summary-level data of BMI was obtained from the Genetic Investigation
122 of ANthropometric Traits (GIANT) consortium, which is a meta-analysis of
123 genome-wide association studies to investigate the genetic associations with height

124 and body mass index in approximately 700,000 individuals of European ancestry.¹⁵
 125 For atrial fibrillation, we used the latest meta-analysis of GWAS, which compared a
 126 total of 60,620 individuals with atrial fibrillation with 970,216 control individuals of
 127 European ancestry from six contributing studies, including the Nord-Trøndelag Health
 128 Study, the Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in
 129 Europe study, the Michigan Genomics Initiative, DiscovEHR, UK Biobank, and the
 130 Atrial Fibrillation Genetics Consortium.¹⁶ The GWAS summary-level data of leptin
 131 derived from the study covering 56,802 samples and 231,001 SNPs.¹⁷ For other
 132 potential mediators, we used GWAS summary data from CARDIoGRAMplusC4D for
 133 coronary heart disease, ISGC Consortium for stroke, FinnGen Consortium for sleep
 134 apnoea, ADIPOGen Consortium for adiponectin, Global Lipids Genetics Consortium
 135 for lipids, International Consortium of Blood Pressure for blood pressure, and UK
 136 biobank for hyperthyroidism. Details of data resources are presented in the
 137 **Supplementary Table 1.**

138 **Genetic instruments selection**

139 We selected all single nucleotide polymorphisms (SNPs) significantly related to BMI
 140 or each mediator from corresponding GWAS summary-level data as instrumental
 141 variables to proxy each exposure, the statistical significance was set at genome-wide
 142 significance levels ($P < 5 * 10^{-8}$). SNPs in linkage disequilibrium were excluded,
 143 which was estimated by r^2 at the cutoff value of 0.001 within 10,000 kb window using
 144 European reference panel from 1000 Genomes Project.

145 **Statistical analyses**

146 **Primary analyses**

147 Two-sample MR analyses were performed by using “TwoSampleMR” R package. In
148 this study, inverse-variance weighted mendelian randomization (IVW-MR) method
149 was applied to obtain the estimates of the causal associations between exposure and
150 outcomes, which is the most widely used approach. The univariable MR analyses
151 were first conducted to evaluate the causal relationship between BMI and AF. Next,
152 we further applied the univariable MR analyses to identify the potential mediated
153 pathways between BMI and AF by screening out the mediators which had causal
154 associations with both BMI and AF. At last, the mediation effect of these identified
155 mediators between BMI and AF was assessed by including these mediators one by
156 one in each multivariable MR model. To further investigate the mediated role of these
157 factors, we calculated the percentage of excess risk mediated (PERM) with odds ratio
158 (OR) as the formula below:

$$159 \quad PERM = \frac{OR - OR_{(mediator\ adjusted)}}{OR - 1} \times 100$$

160 **Sensitivity analyses**

161 Several sensitivity analyses were performed to assess the robustness of the observed
162 results. The Cochran Q test was used to test for the heterogeneity of instrumental
163 variables, in which $p < 0.05$ indicates the presence of heterogeneity. The MR-Egger
164 regression intercept and the MR-PRESSO global test was used to assess the horizontal
165 pleiotropy of instrumental variables. Horizontal pleiotropy refers to the fact that SNPs
166 used as instrumental variables can influence the outcome by means other than
167 exposure. In MR-Egger regression, the intercept indicates horizontal pleiotropy; the

168 closer the value is to 0, the less likely it is that the instrumental variable is
169 horizontally pleiotropic, with $p < 0.05$ suggesting possible horizontal pleiotropy. In
170 MR-PRESSO analysis, global test can be used to test for the presence of horizontal
171 pleiotropy where $P < 0.05$ indicates the presence of horizontal pleiotropy. If the
172 horizontal pleiotropy was present, we further identified the horizontal pleiotropic
173 outliers in MR-PRESSO analysis and applied distortion test to test the difference in
174 the estimates before and after outlier removal, where $p > 0.05$ indicates no statistically
175 significant difference. To further identify the SNP primarily affected by pleiotropy,
176 leave-one-out sensitivity analysis was conducted. This involved removing one SNP at
177 a time and calculating the meta-effect of the remaining SNPs. The analysis observed
178 whether there were any changes in the results after the removal of one SNP. SNPs
179 were then rejected one by one to determine whether they significantly affected the
180 results. R software (version 4.1.0) was used to perform all analyses in this study.

181 **Results**

182 **Univariable MR study for the association of BMI with AF and potential** 183 **mediators**

184 As shown in **Figure 1** and **Supplementary Table 2**, the univariable MR analysis
185 showed a significant causal association between BMI and AF ($OR = 1.41$,
186 $95\%CI = 1.33-1.50$; $P < 0.001$). For the association with potential mediators, we found
187 that higher level of genetically-predicted BMI was significantly associated with a
188 lower level of systolic blood pressure ($OR = 0.58$, $95\%CI = 0.35-0.96$; $P = 0.032$),
189 diastolic blood pressure ($OR = 0.62$, $95\%CI = 0.46-0.84$; $P = 0.002$) and with a higher

level of leptin (OR=1.86, 95%CI=1.68-2.05; $P<0.001$), resistin (OR=1.09, 95%CI=1.02-2.16; $P=0.008$), CRP (OR=1.43, 95%CI=1.37-1.49; $P<0.001$) and a higher incidence of sleep apnoea (OR=2.13, 95%CI=1.93-2.35; $P<0.001$), coronary heart disease (OR=1.54, 95%CI=1.43-1.66; $P<0.001$), stroke (OR=1.22, 95%CI=1.15-1.30; $P<0.001$), and CKD (OR=1.27, 95%CI=1.16-1.40; $P<0.001$).

Univariable MR study for the association of potential mediators with AF

As shown in **Figure 2** and **Supplementary Table 3**, the univariable MR analysis observed significant associations between genetically-predicted higher level of leptin (OR=1.31, 95%CI=1.10-1.55; $P=0.002$), higher level of systolic blood pressure (OR=1.02, 95%CI=1.01-1.02; $P<0.001$), higher level of diastolic blood pressure (OR=1.03, 95%CI=1.02-1.04; $P<0.001$), diagnosis of sleep apnoea (OR=1.18, 95%CI=1.07-1.30; $P=0.001$) or coronary heart disease (OR=1.11, 95%CI=1.05-1.17; $P<0.001$) and higher incidence of AF.

Multivariable MR study for the association of BMI with AF

Univariable MR studies identified several factors related to both BMI and AF, including leptin, systolic blood pressure, diastolic blood pressure, sleep apnoea and coronary heart disease, the multivariable MR analyses were performed to assess the mediation effect of these factors. As shown in **Figure 3** and **Supplementary Table 4**, the observed association between BMI and AF was attenuated from 1.41 (95%CI=1.33-1.50) to 1.21 (95%CI=1.03-1.43) after being adjusted for leptin, in which 48.78% excess risk was mediated. After being adjusted for sleep apnoea or coronary heart disease, the association was attenuated to 1.32(95%CI=1.23-1.43) or

1.33(95%CI=1.26-1.42), respectively. Furthermore, the association between BMI and AF was attenuated to null when being adjusted for leptin and each comorbidity (adjusted for leptin and sleep apnoea: OR = 1.05, 95%CI= 0.85-1.30; adjusted for leptin and coronary heart disease: OR = 1.08, 95%CI= 0.90-1.30), resulting in 87.80% and 80.49% excess risk being mediated, respectively. The observed association between BMI and AF did not change significantly after being adjusted for systolic blood pressure, diastolic blood pressure.

Sensitivity analyses

The results of sensitivity analyses are present in **Supplementary files**. The scatter plots of the main results showed similar results across different MR methods, suggesting the robustness of the main results (**Supplementary Figure 1**). The Cochrane Q test showed that potential heterogeneity was present in most analyses except for BMI on CKD, leptin on AF, adiponectin on AF, sleep apnoea on AF, CKD on AF and hyperthyroidism on AF. While leave-one-out analyses suggested that heterogeneity played a small role in the main results (**Supplementary Figure 2-6**). The results of MR-PRESSO analysis indicated the presence of horizontal pleiotropy in most analyses ($P < 0.05$) while results from distortion test suggested that the presence of horizontal pleiotropy had little impact on the most results ($P > 0.05$) since there was no statistically significant difference in results after outlier removal. Besides, MR-Egger intercept analysis also suggested the absence of horizontal pleiotropy for most reported results ($p > 0.05$) except BMI on coronary heart disease and BMI on hyperthyroidism.

234 Discussion

235 This MR study found causal relationship between BMI and AF, and identified leptin,
236 sleep apnoea and coronary heart disease as the mediators between BMI and AF.
237 Specifically, around half of excess risk of AF related to obesity was mediated by
238 circulating leptin. Furthermore, after adjustment for leptin and specific comorbidity
239 (ie. sleep apnoea or coronary heart disease), the association between BMI and AF
240 completely declined to null, indicating that targeting obesity-induced leptin resistance
241 may be a promising strategy in preventing AF, especially for individuals with sleep
242 apnoea or coronary heart disease.

243 Obesity has been well established as an important risk factor for AF.³⁻⁸ Both
244 traditional observational epidemiological studies and MR studies have provided
245 consistent evidence that obesity is associated with significant excess risk of AF. While
246 the efficacy of weight-loss intervention in AF prevention was less well established,
247 elucidating the underlying pathways between BMI and AF may contribute to
248 providing a more precise strategy for AF prevention.^{18,19} We also found similar results
249 in terms of the positive association between BMI and AF, what's more, circulating
250 leptin was identified as a dominating mediator in the BMI-AF association in present
251 study.

252 Leptin, produced by adipose tissue, holds various regulatory functions in
253 metabolism, immunity, and inflammation.²⁰ It is reported that obesity leads to
254 dramatic rise in circulating levels of leptin, and some experiments revealed that the
255 reduction of leptin levels can impede the progression of obesity.²¹ Elevated leptin

256 levels were demonstrated to be a cardiovascular risk factor.²²⁻²⁴ Some studies have
 257 reported the effect of leptin on AF but provided conflicting conclusions. For example,
 258 a case-control study found that individuals with AF had higher serum leptin levels
 259 compared to the control group.²⁵ A MR study extensively explored the associations
 260 between visceral adipose tissue, circulating protein biomarkers and risk of
 261 cardiovascular diseases where a positive relationship between visceral fat, leptin
 262 levels and the risk of AF was observed.²⁶ However, a prospective cohort study of
 263 postmenopausal women did not uncover a significant correlation between leptin or
 264 adiponectin and risk of AF.²⁷ The exact mechanism by which leptin elevates the risk
 265 of AF remains unclear, although there were some hypotheses. For example,
 266 hyperleptinemia and leptin resistance, both associated with obesity, may contribute to
 267 the growth of left ventricular hypertrophy.²⁸ A review reveals that dysfunction of the
 268 leptin signaling pathway is a significant contributor to obesity and related metabolic
 269 disorders and the effects of the leptin signaling pathway on the cardiovascular system
 270 are mediated through the modulation of cardiomyocyte and endothelial cell function,
 271 among other mechanisms.²⁹ Animal experiments suggests that the signaling of leptin
 272 plays a role in the development of atrial fibrosis and the occurrence of AF triggered
 273 by angiotensin II or high-fat diet.^{30,31}

274 It is surprising that the observed BMI-AF association completely declined to null
 275 in this study after adjustment for leptin and some comorbidity, such as sleep apnoea
 276 and atherosclerotic diseases (eg., coronary heart disease).

277 Obstructive sleep apnoea is a prevalent complication among individuals with

278 obesity.^{32,33} A review has shown that obese individuals suffering from obstructive
279 sleep apnoea have higher level of leptin compared to those without, indicating a
280 positive relationship between obstructive sleep apnoea and leptin resistance.³⁴
281 Additionally, previous research suggests that the disruption of leptin signaling in
282 individuals with obstructive sleep apnoea may result in oxidative stress and increase
283 the risk of cardiovascular diseases.³⁵ A prospective analysis found that nearly half of
284 AF patients suffered from sleep apnoea, while only 32% of the control group did.³⁶
285 Some mechanisms behind the association between obstructive sleep apnoea and the
286 increased risk of AF have been proposed, including recurrent nocturnal
287 hypoxia/hypercapnia, surges in sympathetic tone and blood pressure during apneic
288 episodes, and increased inflammation.^{37,38} These studies suggested interconnects
289 between obesity, leptin, sleep apnoea and AF. This study found that the effect of
290 obesity on AF was totally mediated by leptin and sleep apnoea, indicating that
291 targeting leptin resistance induced by obesity and sleep apnoea may be an effective
292 strategy for preventing AF.

293 Obesity is also associated with coronary heart disease, a risk factor for AF.
294 Leptin secreted by adipose tissue may contribute to the development of
295 atherosclerosis by affecting some types of cells, which may lead to the development
296 of coronary heart disease.²⁴ For example, previous studies suggested that leptin had
297 the potential to enhance platelet aggregation, while which was only observed in obese
298 individuals, suggesting the prothrombotic effect of leptin is probably restricted to
299 individuals with obesity-induced leptin resistance and acts as a mediator between

obesity and cardiovascular diseases.¹⁰ Similarly, this study found that the effect of obesity on AF was totally mediated by leptin and atherosclerotic diseases, suggesting that targeting obesity-induced leptin resistance may be effective in AF prevention through the inhibition of platelet aggregation among individuals at high risk of atherosclerotic diseases or with a history of atherosclerotic diseases. Besides, leptin may directly affect coronary endothelial cells by increasing the expression of tissue factor and cellular adhesion molecules.³⁹

A major advantage of the study was that MR design could reduce the impact of confounding factors and avoid reverse causality as compared with traditional observational epidemiological studies, which can provide complementary evidence for the observational findings and examine the causal relationships between exposure, mediators and outcome. To our knowledge, this is the first MR study to extensively explore the potential mediating pathways between BMI and AF. However, there are several limitations of this study. First, the GWAS summary data used in this study are derived from relevant studies based on European populations, so the generalization of these findings is limited and further studies are needed in populations of other ethnicities. Second, individual-level GWAS data are not publicly available, we are thus not able to examine the associations in subgroup population. For example, previous study showed that there were sex differences in leptin levels, stratified analysis by sex may provide more information regarding the sex-specific mediating role of leptin. Third, sensitivity analyses showed that some instrumental variables may have horizontal pleiotropy, therefore the influence of potential horizontal

322 pleiotropy on the results cannot be completely ruled out.

323 In conclusion, this MR study identified leptin as an important mediator between
324 BMI and AF, suggesting that targeting leptin resistance may be crucial for developing
325 effective prevention and treatment strategies to reduce the risk of obesity-related AF,
326 particularly for individuals with sleep apnoea or coronary heart disease.

327 **Contributors:** All authors were responsible for the study concept and design. WH
328 obtained funding. ZG did the statistical analysis and drafted the manuscript. WH and
329 JX critically revised the manuscript. All authors gave the final approval and agreed to
330 be accountable for all aspects of work ensuring integrity and accuracy.

331 **Data sharing statement:** All raw data are available in the public repository IEU open
332 gwas project (<https://gwas.mrcieu.ac.uk/>).

333 **Declaration of Competing Interest:** The authors declare no competing interests.

334 **Acknowledgments:** We thank the patients and investigators who contributed to the UK
335 Biobank, GIANT Consortium, ADIPOGen, GLGC, International Consortium of Blood
336 Pressure, FinnGen biobank, CARDIoGRAMplusC4D Consortium, ISGC Consortium.

337 **Funding Information:** This work was supported by the Natural Science Foundation
338 of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents
339 of Fujian Medical University (XRCZX2021026) to Dr. Wuqing Huang. The funder
340 had no role in study design, data collection and interpretation, or the decision to
341 submit the work for publication.

342 **References**

- 343 1. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation
344 prevalence, incidence, risk factors, and mortality in the Framingham Heart
345 Study: a cohort study. *Lancet*. 2015;386(9989):154-162.
- 346 2. Kornej J, Borschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial
347 Fibrillation in the 21st Century: Novel Methods and New Insights. *Circ Res*.
348 2020;127(1):4-20.
- 349 3. Feng T, Vegard M, Strand LB, et al. Weight and weight change and risk of atrial
350 fibrillation: the HUNT study. *Eur Heart J*. 2019;40(34):2859-2866.
- 351 4. Wong CX, Sullivan T, Sun MT, et al. Obesity and the Risk of Incident,
352 Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of
353 626,603 Individuals in 51 Studies. *JACC Clin Electrophysiol*. 2015;1(3):139-152.
- 354 5. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of
355 Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A
356 Long-Term Follow-Up Study (LEGACY). *J Am Coll Cardiol*.
357 2015;65(20):2159-2169.
- 358 6. Larsson SC, Back M, Rees JMB, Mason AM, Burgess S. Body mass index and
359 body composition in relation to 14 cardiovascular conditions in UK Biobank: a
360 Mendelian randomization study. *Eur Heart J*. 2020;41(2):221-226.
- 361 7. Chua W, Purmah Y, Cardoso VR, et al. Data-driven discovery and validation of
362 circulating blood-based biomarkers associated with prevalent atrial fibrillation.
363 *Eur Heart J*. 2019;40(16):1268-1276.
- 364 8. Chatterjee NA, Giulianini F, Geelhoed B, et al. Genetic Obesity and the Risk of
365 Atrial Fibrillation: Causal Estimates from Mendelian Randomization.
366 *Circulation*. 2017;135(8):741-754.
- 367 9. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial
368 fibrillation in relation to optimal and borderline risk factors: the
369 Atherosclerosis Risk in Communities (ARIC) study. *Circulation*.
370 2011;123(14):1501-1508.
- 371 10. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of
372 inflammation and metabolism in obesity-related cardiovascular disease. *J Am*
373 *Coll Cardiol*. 2008;52(15):1201-1210.
- 374 11. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial
375 fibrillation. *Nat Rev Cardiol*. 2015;12(4):230-243.
- 376 12. Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial
377 fibrillation. *Eur Heart J*. 2016;37(20):1565-1572.
- 378 13. Sandhu RK, Ezekowitz J, Andersson U, et al. The 'obesity paradox' in atrial
379 fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in
380 Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. *Eur Heart*
381 *J*. 2016;37(38):2869-2878.
- 382 14. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
383 contribute to understanding environmental determinants of disease? *Int J*
384 *Epidemiol*. 2003;32(1):1-22.

- 385 15. Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide
386 association studies for height and body mass index in approximately 700000
387 individuals of European ancestry. *Hum Mol Genet.* 2018;27(20):3641-3649.
- 388 16. Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic
389 discovery yields new insight into atrial fibrillation biology. *Nat Genet.*
390 2018;50(9):1234-1239.
- 391 17. Yaghootkar H, Zhang Y, Spracklen CN, et al. Genetic Studies of Leptin
392 Concentrations Implicate Leptin in the Regulation of Early Adiposity. *Diabetes.*
393 2020;69(12):2806-2818.
- 394 18. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
395 cardiometabolic risk factor management on symptom burden and severity in
396 patients with atrial fibrillation: a randomized clinical trial. *JAMA.*
397 2013;310(19):2050-2060.
- 398 19. Alonso A, Bahnson JL, Gaussoin SA, et al. Effect of an intensive lifestyle
399 intervention on atrial fibrillation risk in individuals with type 2 diabetes: the
400 Look AHEAD randomized trial. *Am Heart J.* 2015;170(4):770-777 e775.
- 401 20. Flier JSJTYjob, medicine. Hormone resistance in diabetes and obesity: insulin,
402 leptin, and FGF21. 2012;85(3):405.
- 403 21. Zhao S, Zhu Y, Schultz RD, et al. Partial Leptin Reduction as an Insulin
404 Sensitization and Weight Loss Strategy. *Cell Metab.* 2019;30(4):706-719 e706.
- 405 22. Sweeney G. Cardiovascular effects of leptin. *Nat Rev Cardiol.* 2010;7(1):22-29.
- 406 23. Jamar G, Caranti DA, de Cassia Cesar H, Masquio DCL, Bandoni DH, Pisani LP.
407 Leptin as a cardiovascular risk marker in metabolically healthy obese:
408 Hyperleptinemia in metabolically healthy obese. *Appetite.* 2017;108:477-482.
- 409 24. Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2
410 diabetes mellitus. *Acta Pharmacol Sin.* 2018;39(7):1176-1188.
- 411 25. Anaszewicz M, Wawrzenczyk A, Czerniak B, et al. Leptin, adiponectin, tumor
412 necrosis factor alpha, and irisin concentrations as factors linking obesity with
413 the risk of atrial fibrillation among inpatients with cardiovascular diseases.
414 *Kardiol Pol.* 2019;77(11):1055-1061.
- 415 26. Huang Y, Liu Y, Ma Y, et al. Associations of Visceral Adipose Tissue, Circulating
416 Protein Biomarkers, and Risk of Cardiovascular Diseases: A Mendelian
417 Randomization Analysis. *Front Cell Dev Biol.* 2022;10:840866.
- 418 27. Ermakov S, Azarbal F, Stefanick ML, et al. The associations of leptin,
419 adiponectin and resistin with incident atrial fibrillation in women.
420 2016;102(17):1354-1362.
- 421 28. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and Atrial
422 Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss
423 and Exercise. *J Am Coll Cardiol.* 2017;70(16):2022-2035.
- 424 29. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular
425 consequences. *Circ Res.* 2007;101(6):545-559.
- 426 30. Fukui A, Takahashi N, Nakada C, et al. Role of leptin signaling in the
427 pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. *Circ*
428 *Arrhythm Electrophysiol.* 2013;6(2):402-409.

- 429 31. Fukui A, Ikebe-Ebata Y, Kondo H, et al. Hyperleptinemia Exacerbates High-Fat
430 Diet-Mediated Atrial Fibrosis and Fibrillation. *J Cardiovasc Electrophysiol.*
431 2017;28(6):702-710.
- 432 32. Xiao Q, Gu F, Caporaso N, Matthews CE. Relationship between sleep
433 characteristics and measures of body size and composition in a
434 nationally-representative sample. *BMC Obes.* 2016;3:48.
- 435 33. Ma Y, Peng L, Kou C, Hua S, Yuan H. Associations of Overweight, Obesity and
436 Related Factors with Sleep-Related Breathing Disorders and Snoring in
437 Adolescents: A Cross-Sectional Survey. *Int J Environ Res Public Health.*
438 2017;14(2).
- 439 34. Muscogiuri G, Barrea L, Annunziata G, et al. Obesity and sleep disturbance:
440 the chicken or the egg? *Crit Rev Food Sci Nutr.* 2019;59(13):2158-2165.
- 441 35. Berger S, Polotsky VY. Leptin and Leptin Resistance in the Pathogenesis of
442 Obstructive Sleep Apnea: A Possible Link to Oxidative Stress and
443 Cardiovascular Complications. *Oxid Med Cell Longev.* 2018;2018:5137947.
- 444 36. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and
445 obstructive sleep apnea. *Circulation.* 2004;110(4):364-367.
- 446 37. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural
447 mechanisms in obstructive sleep apnea. *J Clin Invest.* 1995;96(4):1897-1904.
- 448 38. Otto ME, Belohlavek M, Romero-Corral A, et al. Comparison of cardiac
449 structural and functional changes in obese otherwise healthy adults with
450 versus without obstructive sleep apnea. *Am J Cardiol.* 2007;99(9):1298-1302.
- 451 39. Cirillo P, Angri V, De Rosa S, et al. Pro-atherothrombotic effects of leptin in
452 human coronary endothelial cells. *Thromb Haemost.* 2010;103(5):1065-1075.

453

454 **Figure legends:**

455 **Figure 1:** Association of body mass index with atrial fibrillation and mediators in the
456 univariable MR analysis.

457 **Figure 2:** Association of mediators with the risk of atrial fibrillation in the univariable
458 MR analysis.

459 **Figure 3:** Association of body mass index with the risk of atrial fibrillation in the
460 multivariate MR analysis.





